Rare Site Primary Soft tissue Neuroendocrine Tumour with metastases and near-complete resolution with 177Lu-DOTATATE: documenting a Promising Clinical Application of Peptide Receptor Radionuclide Therapy.
Neuroendocrine tumours (NETs) of the skin or soft tissue are rare tumors (mostly described as site of metastasis), while primary soft tissue neuroendocrine tumours are extremely rare; they are usually diagnosed at advanced stages with distant metastases due to their indolent nature. We herein describe our experience with two such cases. In the first case, the NET originated in the retroperitoneal soft tissue and the second patient was a middle aged lady with NET arising from soft tissue in the pelvis. Both patients were treated with 177Lu-DOTATATE in view of SSTR expressing metastatic lesions, demonstrating excellent outcome reflected by complete metabolic response and near-complete anatomical response to the administered PRRT. The noteworthy factors of the reported cases were: (i) unusual sites of primary tumour and (ii) near-complete to complete symptomatic, anatomical and metabolic resolution of the recurrent primary tumour and metastatic lesions with PRRT alone. NETs arising from the rare anatomical locations are usually non-functioning with good clinical outcomes and 177Lu-DOTATATE PRRT can be considered a promising therapeutic modality in patients with metastatic or advanced disease.